REPL

Conviction 59HealthcareScan · Thu, Jun 25, 2026

Shooting star

REPL$11.12-1.33%

ResistanceSupportVol 14Insider sell

Vol MA14 2.87M

Mar 26Apr 14May 1May 19Jun 8Jun 25

Replimune Group, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.replimune.com ↗

Price11.12

Change-1.33%

Gap-0.27%

Rel volume0.48×

Avg volume6.33M

Avg $ vol58.19M

SMA 209.38

SMA 505.86

SMA 2007.16

Price vs 50+89.89%

Price vs 200+55.35%

MA stackmixed

50/200 cross—

Supertrendup · 8.77

RSI (14)72

MACD hist0.10

MACD crossbull · 5d

Stoch %K / %D72 / 76

ADX (14)46

+DI / −DI40 / 11

RSI divergence—

MACD divergence—

ATR %+8.00%

ADR %9.46%

52w high12.63

52w low1.70

From 52w high-11.96%

Above 52w low+554.12%

New 52w highNo

SqueezeOff

Bollinger width61.04%

%B0.80

Donchian pos85.45%

Donchian high12.23

Donchian low4.60

AVWAP (52w high)5.91

vs AVWAP high+88.30%

AVWAP (52w low)4.72

vs AVWAP low+135.37%

OBV trendUp

Chaikin MF (20)0.05

Today vs 20d0.48×

Avg vol (14d)2.87M

Avg vol (20d)6.33M

Avg $ vol (20d)58.19M

Market cap918.21M

RS 3m (vs SPY)+49.44%

RS 6m (vs SPY)+6.33%

RS line new highNo

Trend template7/8

Technical rank87.4

1 week+11.20%

1 month+141.74%

3 months+47.09%

6 months+11.98%

1 year+14.05%

YTD+24.94%

P/E-3.71

P/B4.36

P/S—

P/FCF-4.72

EPS-3.07

Div yield—

ROE-117.46%

ROA-74.13%

Debt/Eq0.23

Current5.60

EV/EBITDA-3.27

Gross margin—

Net margin—

Rev growth—

EPS growth-14.60%

Price target4.20

Target upside-62.23%

Analyst ratingHold

Institutional102.83%

Ent. value842.88M

Revenue0

Net income-70.93M

Gross profit—

Free cash flow-194.52M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out82.57M

Employees479

ListedFri, Jul 20, 2018

Free float62.65M

Float %75.9%

Short interest25.95M

Days to cover2.9d

Short volume49.9%

Squeeze score61 / 100

Next earningsThu, Jun 25, 2026 (0d)

EPS forecast−$0.73 · 5 est

Last EPS vs est−$0.77 vs −$0.85

Last surprise+9.4% beat

Setup gradeC

Conviction59 / 100

Pattern quality—

Tech rank87.4 / 100

Group rank50 / 100

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmShooting star

News sentiment—

Financials as of Wed, Dec 31, 2025 · quarterly.

Signal lifecycle

How this symbol has moved through the lanes across 17 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.

Setting up
Jun 18
1 scan
→
Breaking out now
Jun 22
1 scan

Congress activity

Disclosed STOCK Act trades in REPL

All disclosures →

No recent disclosed trades by Congress in REPL. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in REPL · 7 sells

Insider	Side	Shares	Value	Traded	Filed
Sarchi Christopher Chief Commercial Officer · Common Stock · 2026-06-01	Sell	12K	$111K	2026-06-01	2026-06-03
Xynos Konstantinos Chief Medical Officer · Common Stock · 2026-05-18	Sell	14.02K	$71K	2026-05-18	2026-05-20
Sarchi Christopher Chief Commercial Officer · Common Stock · 2026-05-18	Sell	8.63K	$44K	2026-05-18	2026-05-20
Patel Sushil Chief Executive Officer · Common Stock · 2026-05-18	Sell	37.32K	$190K	2026-05-18	2026-05-20
Schwendenman Andrew Chief Accounting Officer · Common Stock · 2026-05-18	Sell	7.89K	$40K	2026-05-18	2026-05-20
Hill Emily Luisa Chief Financial Officer · Common Stock · 2026-05-18	Sell	7.81K	$40K	2026-05-18	2026-05-20
Astley-Sparke Philip Director · Common Stock · 2026-05-18	Sell	17.66K	$90K	2026-05-18	2026-05-20

SEC filings

EDGAR filings in REPL

EDGAR →

No recent SEC filings on file for REPL.

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.